At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
AIM AIM ImmunoTech
Market Closed 02-14 16:00:00 EST
0.1290
-0.0096
-6.93%
盘后0.1242
-0.0048-3.72%
19:53 EST
High0.1400
Low0.1202
Vol2.16M
Open0.1400
D1 Closing0.1386
Amplitude14.29%
Mkt Cap8.87M
Tradable Cap8.08M
Total Shares68.75M
T/O279.92K
T/O Rate3.45%
Tradable Shares62.61M
P/B--
ROE--
EPS0.00
52wk High--
52wk Low--
P/E--
Dividend--
Div.Yield--
ROA--
Argo Group Extends Tender Offer Deadline Amid AIM Delisting Plans
AIM ImmunoTech Announces That It Will Not Proceed With an Offering Pursuant to Its Registration Statement on Form S-1 Until After It Files Its Annual Report on Form 10-K for the Fiscal Year Ended December 31, 2024
AIM ImmunoTech Announces a Planned Follow-up Clinical Study Evaluating a Combination Treatment of Aim’s Ampligen® and AstraZeneca’s Flumist® to Address the Recent Avian Influenza Outbreaks
AIM ImmunoTech announces a planned follow-up clinical study evaluating a combination treatment of AIM’s Ampligen® and AstraZeneca’s FluMist® to address the recent avian influenza outbreaks
AIM ImmunoTech Inc., an immuno-pharma company, focuses on the research and development of therapeutics to treat multiple types of cancers, viral diseases, and immune-deficiency disorders in the United States. The company's lead product candidate is Ampligen, a drug of macromolecular ribonucleic acid molecules for the treatment of chronic fatigue syndrome (CFS). It is also developing Ampligen for the treatment of renal cell carcinoma, malignant melanoma, non-small cell lung, ovarian, breast, colorectal, prostate and pancreatic cancer, myalgic encephalomyelitis, Hepatitis B, HIV, COVID-19, and post-COVID conditions. In addition, the company provides Alferon N Injection, an injectable formulation of natural alpha interferon to treat human papilloma viruses, and genital warts, a sexually transmitted disease. AIM ImmunoTech Inc. has agreements with Amarex Clinical Research LLC; Pharmaceutics International Inc.; Polysciences Inc.; and University of Cagliari Dipartimento di Scienze della Vita e dell'Ambiente. The company was formerly known as Hemispherx Biopharma, Inc. and changed its name to AIM ImmunoTech Inc. in August 2019. AIM ImmunoTech Inc. was incorporated in 1966 and is headquartered in Ocala, Florida.